CN106566838A - MiR-126 full-length gene knockout kit based on CRISPR-Cas9 technology and application thereof - Google Patents
MiR-126 full-length gene knockout kit based on CRISPR-Cas9 technology and application thereof Download PDFInfo
- Publication number
- CN106566838A CN106566838A CN201611002317.4A CN201611002317A CN106566838A CN 106566838 A CN106566838 A CN 106566838A CN 201611002317 A CN201611002317 A CN 201611002317A CN 106566838 A CN106566838 A CN 106566838A
- Authority
- CN
- China
- Prior art keywords
- sgrna
- seq
- mir
- puro
- plasmid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091028066 Mir-126 Proteins 0.000 title claims abstract description 115
- 238000005516 engineering process Methods 0.000 title claims abstract description 23
- 238000003209 gene knockout Methods 0.000 title claims abstract description 16
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 title claims abstract description 15
- 210000004027 cell Anatomy 0.000 claims abstract description 136
- 108091027544 Subgenomic mRNA Proteins 0.000 claims abstract description 96
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 66
- 108091033409 CRISPR Proteins 0.000 claims abstract description 35
- 238000012163 sequencing technique Methods 0.000 claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 25
- 238000011144 upstream manufacturing Methods 0.000 claims abstract description 16
- 239000013612 plasmid Substances 0.000 claims description 74
- 108020004414 DNA Proteins 0.000 claims description 30
- 238000012360 testing method Methods 0.000 claims description 29
- 239000012634 fragment Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 23
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 20
- 241000894006 Bacteria Species 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 14
- 238000013461 design Methods 0.000 claims description 12
- 238000012408 PCR amplification Methods 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 238000010008 shearing Methods 0.000 claims description 8
- 239000013598 vector Substances 0.000 claims description 7
- 239000002299 complementary DNA Substances 0.000 claims description 6
- 108020004635 Complementary DNA Proteins 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 238000010804 cDNA synthesis Methods 0.000 claims description 5
- 239000013600 plasmid vector Substances 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 230000008901 benefit Effects 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 102000012410 DNA Ligases Human genes 0.000 claims description 3
- 108010061982 DNA Ligases Proteins 0.000 claims description 3
- 108010042407 Endonucleases Proteins 0.000 claims description 3
- 102000004533 Endonucleases Human genes 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 230000029087 digestion Effects 0.000 claims description 3
- 210000003725 endotheliocyte Anatomy 0.000 claims description 3
- 210000004881 tumor cell Anatomy 0.000 claims description 3
- 238000000137 annealing Methods 0.000 claims description 2
- 239000013613 expression plasmid Substances 0.000 claims description 2
- 238000001890 transfection Methods 0.000 abstract description 22
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract description 9
- 201000005202 lung cancer Diseases 0.000 abstract description 6
- 208000020816 lung neoplasm Diseases 0.000 abstract description 6
- 210000003556 vascular endothelial cell Anatomy 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 238000012795 verification Methods 0.000 abstract description 3
- 238000007873 sieving Methods 0.000 abstract 2
- 108700011259 MicroRNAs Proteins 0.000 description 30
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 28
- 238000010586 diagram Methods 0.000 description 15
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 11
- 230000004087 circulation Effects 0.000 description 10
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 206010006187 Breast cancer Diseases 0.000 description 8
- 208000026310 Breast neoplasm Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 8
- 238000011529 RT qPCR Methods 0.000 description 7
- 238000010459 TALEN Methods 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000012097 Lipofectamine 2000 Substances 0.000 description 6
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 239000011543 agarose gel Substances 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 229950010131 puromycin Drugs 0.000 description 4
- 108091028113 Trans-activating crRNA Proteins 0.000 description 3
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 230000011559 double-strand break repair via nonhomologous end joining Effects 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 210000005075 mammary gland Anatomy 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000001685 thyroid gland Anatomy 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108020005004 Guide RNA Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 102100037614 Sprouty-related, EVH1 domain-containing protein 1 Human genes 0.000 description 2
- 101710112213 Sprouty-related, EVH1 domain-containing protein 1 Proteins 0.000 description 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000012496 blank sample Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000005265 lung cell Anatomy 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000006780 non-homologous end joining Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000003606 umbilical vein Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 101100380241 Caenorhabditis elegans arx-2 gene Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 102100021090 Homeobox protein Hox-A9 Human genes 0.000 description 1
- 101001057156 Homo sapiens Melanoma-associated antigen C2 Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 108700012928 MAPK14 Proteins 0.000 description 1
- 102100027252 Melanoma-associated antigen C2 Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108091062154 Mir-205 Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000012500 Proto-Oncogene Proteins c-crk Human genes 0.000 description 1
- 108091027568 Single-stranded nucleotide Proteins 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 101710160666 Vascular cell adhesion protein 1 Proteins 0.000 description 1
- 208000035868 Vascular inflammations Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 101150092805 actc1 gene Proteins 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 238000005267 amalgamation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229940126587 biotherapeutics Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000010005 growth-factor like effect Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 108010027263 homeobox protein HOXA9 Proteins 0.000 description 1
- 238000013095 identification testing Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000013139 quantization Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000008470 skin growth Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000006459 vascular development Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Landscapes
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a MiR-126 full-length gene knockout kit based on a CRISPR-Cas9 technology and an application thereof. CRISPR-Cas9 target sequences upstream and downstream a MiR-126 gene are preferably selected, and sgRNA single strands are designed and synthesized for the target sequences and built into a carrier. Through 293T cell strain transfection, sgRNA and trRNA constitute a specific recognition structure. Thus, Cas9 enzyme is guided to specifically shear the corresponding sequences at the two ends of the MiR-126 gene. Drug sieving is carried out constantly to get a MiR-126 full-length gene knockout cell strain. An optimal upstream and downstream sgRNA combination is obtained through drug sieving cell strain sequencing verification. The knockout efficiency of the combination is as high as 90% above. The kit built based on the combination can be used to carry out specific MiR-126 full-length gene knockout on a variety of cell lines such as 293T, a lung cancer cell line A 549 and a vascular endothelial cell HUVEC line.
Description
Technical field
The invention belongs to genetic engineering field, is related to a kind of miR-126 gene knockouts test kit, more particularly to one kind is based on
CRISPR-Cas9 technologies can carry out the test kit that specificity is knocked out completely to miR-126 full-length gene orders.Additionally, this
The bright application for also disclosing the test kit.
Background technology
MicroRNA (microRNA) is that a class is single-stranded by the non-coding that the length of endogenous gene is about 22 nucleotide
RNA molecule, is widely distributed in virus, plant in higher mammal, and it has in the cell various important adjustment effects.
Each microRNA can have multiple target genes, and several microRNA can also adjust same gene.This complicated tune
Section network both can regulate and control the expression of multiple genes by a microRNA, it is also possible to by the combination of several microRNA
Carry out the expression of certain gene of finely regulating, therefore the gene function of microRNA is explored and application and development is always study hotspot.
MiR-126 (microRNA126, microRNA 126) is positioned at the skins somatomedin domain 7 of human chromosomal 9q34.3
In the intron of (epidermal growth factor like 7, EFGL7) gene.MiR-126 is that a kind of blood vessel endothelium is thin
The specific expressed microRNA of born of the same parents, is highly expressed in the abundant tissue of vascularization, such as in heart, lungs, kidney.It can
By regulating and controlling Spred-1, (Sprouty-related, EVH1 domain-containing protein 1, Sprouty is related
Region protein containing EVH1 1), VCAM-1 (Vascular cell adhesion protein 1, vascular cell adhesion molecule-1),
HoxA9 (homeobox A9, hox geneses A9), v-Crk (Sarcoma Virus CT10regulator of kinase,
Sarcoma virus CT10 adjusts kinases), EGFL-7 and VEGF (vascular endothelial growth factor, Ink vessel transfusing
Skin growth factor) isogenic expression participates in adjusting vascular development, new vesselses and formed and the blood vessel such as vascular inflammation reaction
Physiology and pathophysiological process.Jing other researchs find, miR-126 in gastrointestinal tract, genital cancers, mammary gland, thyroid, lung,
And express suppressed in some other cancer.Lower and can induce after miR-126 cancer cell multiplication, migration is attacked and affected
The cell survival phase, there is dependency between miR-126 downwards are bad with kinds cancer existence.These researchs are found to be gastrointestinal tract,
The prevention of the cancer metastasiss such as genital cancers, mammary gland, thyroid, lung judges to provide potential target, and for gastrointestinal tract, reproductive tract
The Biotherapeutics of the cancers such as cancer, mammary gland, thyroid, lung indicate new direction, point out the importance and necessity of miR-126 researchs
Property.
Because microRNA sequences are shorter and its precursor has loop-stem structure, classical RNA disturbs the method for (RNAi) not
The functional study of expression is lowered suitable for microRNA.The conventional method of microRNA researchs at present, is Applied Biology technology
In vivo in cell model or external dynamic/plant model, microRNA is carried out into sequence closing or deletion mutant is caused,
Negative regulation effect reduction or remove that simulation microRNA afunction causes, and then study its function mechanism, technology
Method mainly has two classes:
First kind method is the complementary closure sequence of design synthesis microRNA, and complementary seriess were originally specific with microRNA
With reference to mRNA formed competition, reduction microRNA to specific mRNA binding abilities and regulating and controlling effect.Due to complementary seriess be with
The form of base complementrity is closed to microRNA, does not directly result in microRNA degradeds or the downward expressed, so
The expression of microRNA does not change, and can be to the closing efficiency of microRNA functions without direct technical method
Carry out quantization detection, it is impossible to directly prove that the function of microRNA receives shielding, can only be possible by detection microRNA
Regulation and control downstream gene change carrys out the function of side light microRNA and is suppressed, thus the method is to microRNA functional studies
Verity and effectiveness there is large effect.
Equations of The Second Kind method is with transcriptional activation sample effector nuclease (transcription activator-like
Effector nuclease, TALEN) TALEN technologies, by DNA identification modules by the DNA positions of TALEN element targeting specifics
Put and combine, the shearing of specific site is then completed in the presence of FokI nucleases, DNA level can be carried out to microRNA
Shearing and modification, simulate microRNA afunction.But TALEN technologies rely on what DNA was combined to the knockout of target gene
Amino acid polymer sequence of modules, single TALEN modules carry out assembling needs substantial amounts of molecular cloning and sequencing procedures, very
It is loaded down with trivial details, if all working completes basic experiment operation in laboratory internal to need to take more than 2 months, if screening stably knocks out base
The cell line of cause is needed more than 4 months, and time-consuming for whole process, high cost.
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats/cas,
Cluster, regular intervals short palindrome repetitive sequence) technology is also called CRISPR/Cas9 (CRISPR associated
Protein 9, CRISPR associated protein 9) nucleic acid zymotechnic is a kind of most emerging genome edit tool, it can be completed
DNA identifications and edit that RNA is oriented to.Compared with the gene technology instrument of above-mentioned introduction, CRISPR technologies are physically easier to perform, and have
Higher extensibility.
CRISPR/Cas9 is found in the natural immune system of antibacterial, and its major function is the disease of antagonism invasion
Poison and foreign DNA, are the acquired immunity defense mechanisms of antibacterial and archeobacteria.In this system, crRNA (CRISPR-
Derived RNA, CRISPR derive RNA) by base pairing and tracrRNA (trans-activating RNA, it is trans to swash
RNA living) double-stranded RNA is combined to form, this tracrRNA/crRNA binary complex instructs Cas9 nuclease proteins to guide in crRNA
Double-stranded DNA is sheared in the site that targets of sequence, so as to reach the purpose sheared to genomic DNA or modified.
In order to realize that, using CRISPR/Cas9 systems in mammal, scientist is transformed CRISPR/Cas9,
TracrRNA/crRNA binary complex amalgamation and expression is formed into single-stranded guiding RNA.And in actual design, only design
The RNA sequence of one section of 20nt (base) left and right of synthesis identification target sequence and referred to as sgRNA (small guide RNA, little guide
RNA), other parts are oriented to RNA and exist as the carrier sequence on sgRNA expression vectors because sequence is constant.Therefore, extensively
Using CRISPR/Cas9 systems become and target gene carried out calmly into the Cas9 nucleases under being instructed by the guidings RNA containing sgRNA
To the technology of editor.
The fixed point shearing editing technique of CRISPR/Cas9 technologies is most commonly for Single locus design sgRNA guiding
Cas9 is oriented shearing in target sequence, and (for example, " one kind is based on disclosed in Chinese invention patent application CN105112445A
The miR-205 gene knockout test kits of CRISPR-Cas9 gene Knockouts "), intracellular intrinsic nonhomologous end after cutting
Connection approach (NHEJ) repair process, can introduce radom insertion and the gene mutation deleted, and this repair process is not artificially controlled
System, causes all kinds of unnecessary and inaccurate sequence to insert and delete, and Jing often produces indefinite or invalid cell phenotype, right
Research has a negative impact.
At present, there is not yet about being carried out the full-length gene order of miR-126 using CRISPR/Cas9 systemic characteristics ground
The report of knockout.
The content of the invention
One of the technical problem to be solved in the present invention is to provide a kind of CRISPR/Cas9 gene editing technologies that are based on to miR-
126 genes carry out the test kit of gene knockout, and it allows CRISPR/Cas9 to target miR-126 gene coded sequences two
The shearing that end is pinpointed simultaneously, can greatly avoid guiding Cas9 in target for Single locus design sgRNA using traditional
The probability that non-homologous end joining approach NHEJ caused by shearing institute introduces random mutation generation is oriented in mark sequence, it is non-
Often be conducive to producing and be directed to the single and obvious cell phenotype that the gene is deleted completely, the test kit can efficient, quick, essence
Really, stably realize that miR-126 complete encoding sequences are completely knocked out in genomic level.
The two of the technical problem to be solved in the present invention are to provide the application of the test kit, and the test kit can be applicable to various thin
Born of the same parents' type (for example, vascular endothelial cell, and Several Kinds of Malignancy is such as:Breast carcinoma, pulmonary carcinoma etc.) miR-126 gene knockouts,
These cell lines further can build animal model by the transplanted tumor in nude mice body, be the research of miR-126 related pathways
And the internal and external experimental construction model of drug development etc. provides good tool.
The present invention is by target software design preferably a number of miR-126 upstream region of gene and downstream CRISPR-
Cas9 target sequence, the sgRNA for separately designing synthesis for upstream and downstream target sequence is single-stranded, and is building up to plasmid vector
In, by transfecting 293T cell strains, sgRNA and trRNA (trans-activating RNA) constitutes special identification structure, from
And guide Cas9 enzymes specifically to shear the corresponding sequence at miR-126 genes two ends, and continue medicine sieve, obtain miR-126 full-length genes
The cell strain of knockout.By extracting cell DNA, PCR amplifications, and the goldstandard skill detected with DNA level gene knockout
Art --- generation sequencing technologies are determined and verify, obtain two groups of miR-126 gene knockout CRISPR-Cas9 it is effective on
Downstream sgRNA is combined, and fluorescent quantitative PCR technique shows that the combination realizes that miR-126 molecules knock out efficiency high up to more than 90%, with
This structure applies test kit, can be to 293T, lung cancer cell line A549, breast cancer cell line T47D and vascular endothelial cell
Polytype cell line such as HUVEC systems carries out the total length miR-126 gene order of stable specificity exactly and knocks out.
To solve above-mentioned technical problem, the present invention is adopted the following technical scheme that:
In one aspect of the invention, there is provided a kind of miR-126 full-length genes based on CRISPR-Cas9 technologies knock out reagent
Box,
The test kit is included by plasmid pSpCas9 (BB) -2A-Puro-sgRNA1 and plasmid pSpCas9 (BB) -2A-
The sgRNA plasmid combinations of Puro-sgRNA3 compositions;Plasmid pSpCas9 (the BB) -2A-Puro-sgRNA1, containing one section mutually
The DNA sequence of benefit, the DNA sequence can be transcribed into miR-126 full-length gene of the specific recognition sequence as shown in SEQ ID NO.2
Target sequence sgRNA, the sgRNA can constitute special identification structure with trRNA, so that guiding Cas9 enzymes are specifically sheared
MiR-126 gene pairss answer sequence;Plasmid pSpCas9 (the BB) -2A-Puro-sgRNA3, the DNA sequence containing one section of complementation,
The DNA sequence can be transcribed into the target sequence of miR-126 full-length gene of the specific recognition sequence as shown in SEQ ID NO.4
SgRNA, the sgRNA can constitute special identification structure with trRNA, so that guiding Cas9 enzymes specifically shear miR-126 genes
Correspondence sequence;
Or, the test kit include by plasmid pSpCas9 (BB) -2A-Puro-sgRNA2 and plasmid pSpCas9 (BB) -
The sgRNA plasmid combinations of 2A-Puro-sgRNA5 compositions;Plasmid pSpCas9 (the BB) -2A-Puro-sgRNA2, containing one section
Complementary DNA sequence, the DNA sequence can be transcribed into miR-126 total length base of the specific recognition sequence as shown in SEQ ID NO.3
The sgRNA of the target sequence of cause, the sgRNA can constitute special identification structure with trRNA, so that guiding Cas9 enzymes are specifically cut
Cut miR-126 gene pairss and answer sequence;Plasmid pSpCas9 (the BB) -2A-Puro-sgRNA5, the DNA sequences containing one section of complementation
Row, the DNA sequence can be transcribed into the target sequence of miR-126 full-length gene of the specific recognition sequence as shown in SEQ ID NO.6
The sgRNA of row, the sgRNA can constitute special identification structure with trRNA, so that guiding Cas9 enzymes specifically shear miR-126
Gene pairss answer sequence.
As currently preferred technical scheme, the complementation that plasmid pSpCas9 (the BB) -2A-Puro-sgRNA1 contains
DNA sequence is SEQ ID NO.7 and SEQ ID NO.8.
As currently preferred technical scheme, the complementation that plasmid pSpCas9 (the BB) -2A-Puro-sgRNA3 contains
DNA sequence is SEQ ID NO.11 and SEQ ID NO.12.
As currently preferred technical scheme, the complementation that plasmid pSpCas9 (the BB) -2A-Puro-sgRNA2 contains
DNA sequence is SEQ ID NO.9 and SEQ ID NO.10.
As currently preferred technical scheme, the complementation that plasmid pSpCas9 (the BB) -2A-Puro-sgRNA5 contains
DNA sequence is SEQ ID NO.15 and SEQ ID NO.16.
As currently preferred technical scheme, plasmid pSpCas9 (the BB) -2A-Puro-sgRNA1 and plasmid
The sgRNA plasmid combinations of pSpCas9 (BB) -2A-Puro-sgRNA3 compositions, plasmid pSpCas9 (the BB) -2A-Puro-
The sgRNA plasmid combinations of sgRNA2 and plasmid pSpCas9 (BB) -2A-Puro-sgRNA5 compositions are with the side for comprising the steps
What method built:
Step one, by target software design preferably a number of miR-126 upstream region of gene and downstream CRISPR-
Cas9 target sequence, it is specific as follows:
Upstream:
sgRNA-1:TAATGTCCCGTCGCCAGCGG, as shown in SEQ ID NO.2;
sgRNA-2:GCCACGCCTCCGCTGGCGAC, as shown in SEQ ID NO.3;
Downstream:
sgRNA-3:TCTCAGCGGCGTTTTCGATG, as shown in SEQ ID NO.4;
sgRNA-4:GAGTAATAATGCGCCGTCCA, as shown in SEQ ID NO.5;
sgRNA-5:TTTCGATGCGGTGCCGTGGA, as shown in SEQ ID NO.6;
Step 2, separately designs sgRNA fragment of the synthesis for upstream and downstream target sequence, and is building up to plasmid vector
In;The sgRNA fragment sequences are as follows:
sgRNA-1F:CcacgTAATGTCCCGTCGCCAGCGG, as shown in SEQ ID NO.7;
sgRNA-1R:AaacCCGCTGGCGACGGGACATTAc, as shown in SEQ ID NO.8;
sgRNA-2F:CcacGCCACGCCTCCGCTGGCGAC, as shown in SEQ ID NO.9;
sgRNA-2R:Aaac GTCGCCAGCGGAGGCGTGGC, as shown in SEQ ID NO.10;
SgRNA-3F ccacgTCTCAGCGGCGTTTTCGATG, as shown in SEQ ID NO.11;
SgRNA-3R aaacCATCGAAAACGCCGCTGAGAC, as shown in SEQ ID NO.12;
SgRNA-4F ccacGAGTAATAATGCGCCGTCCA, as shown in SEQ ID NO.13;
SgRNA-4R aaacTGGACGGCGCATTATTACTC, as shown in SEQ ID NO.14;
SgRNA-5F ccacgTTTCGATGCGGTGCCGTGGA, as shown in SEQ ID NO.15;
SgRNA-5R aaacTCCACGGCACCGCATCGAAAc, as shown in SEQ ID NO.16;
Step 3, by transfecting 293T cell strains, sgRNA and trRNA constitutes special identification structure, so as to guide Cas9
Enzyme specifically shears the corresponding sequence at miR-126 genes two ends, continues medicine sieve, obtains the cell of miR-126 full-length genes knockout
Strain;
Step 4, by extracting cell DNA, PCR amplifications, sequencing is determined and verifies, obtains the two groups of miR- for optimizing
The sgRNA plasmid combinations of 126 gene knockout CRISPR-Cas9, i.e., described plasmid pSpCas9 (BB) -2A-Puro-sgRNA1 and
The sgRNA plasmid combinations of plasmid pSpCas9 (BB) -2A-Puro-sgRNA3 compositions, and the plasmid pSpCas9 (BB) -2A-
The sgRNA plasmid combinations of Puro-sgRNA2 and plasmid pSpCas9 (BB) -2A-Puro-sgRNA5 compositions.
It is described to be building up in plasmid vector in step 2 as currently preferred technical scheme, specifically include following step
Suddenly:
(1) with pSpCas9 (BB) -2A-Puro plasmids as initial vector, single endonuclease digestion is carried out with Bbs I, to linearized vector
Carry out purification;
(2) synthetic sgRNA fragments are diluted and is annealed;
(3) the sgRNA fragment phases after linearizing pSpCas9 (BB) -2A-Puro is annealed together using T4DNA ligases
Even, whole connection products are added into the conversion of bacillus coli DH 5 alpha competent cell;
(4) single bacterium colony that the flat board of DH5 α competent cells bacterium solution coating after conversion grows is carried out using bacterium colony PCR methods
Identification, obtains expression plasmid.
In another aspect of this invention, there is provided mentioned reagent box is in cell line miR-126 gene knockout product is prepared
Using.The cell line includes vehicles cells system 293T, tumor cell line (for example, lung cancer cell line A549, breast cancer cell line
) and endotheliocyte HUVEC systems T47D.
Compared with prior art, the present invention has the advantages that:MiR- of the present invention based on CRISPR-Cas9 technologies
126 full-length genes knock out test kit, mainly knock out miR-126 genes of interest using CRISPR/Cas9 systems.This is to utilize first
CRISPR/Cas9 systemic characteristics are knocked out miR-126 full-length gene orders.The invention has the advantages that:
1. the drawbacks of overcoming tradition closing sequence method research microRNA functions, miR-126 knocks out result can quantify prison
Survey, miR-126 molecules knock out efficiency high up to more than 90%;
2. the time-consuming loaded down with trivial details defect of TALEN technologies is overcome, cell screening is accelerated and is tested and be reduced to 1 week, it is stable
Cell line experiments are built to 2 months;Construction step and experimental implementation are simple, while reducing reagent cost consumption;
3. technology extending design has been done in CRISPR-Cas9 technologies, at the upstream and downstream two ends of miR-126 gene orders all
Design sgRNA, carries out fixed point shearing while two sites, realizes on DNA level complete to whole miR-126 gene orders
Whole knockout (see Figure 15), generation sequencing result shows, experiment effect, good stability can be repeated in various kinds of cell.Pole of the present invention
The earth avoids being led for being oriented cutting method in Single locus design sgRNA guiding Cas9 target sequence using traditional
Cause non-homologous end joining approach NHEJ to introduce the probability that random mutation occurs, can accurately realize that microRNA total lengths are compiled
Code sequence is completely knocked out in genomic level.
Description of the drawings
Fig. 1 is PCR methods checking pSpCas9 (BB) -2A-Puro-sgRNA vector construction schematic diagrams in the embodiment of the present invention 1;
Wherein, passage 1-5 is pSpCas9 (BB) -2A-Puro-sgRNA vector construction positive colony PCR results;Passage M is DNA molecular
Amount standard.
Fig. 2 is pSpCas9 (BB) -2A-Puro-sgRNA1 and pSpCas9 (BB) -2A-Puro- in the embodiment of the present invention 2
SgRNA3 pairing sgRNA combinations knock out result schematic diagram in 293T;Wherein, passage 3,4,5 is pSpCas9 (BB) -2A-
Puro-sgRNA1 and pSpCas9 (BB) -2A-Puro-sgRNA3 combinations knock out PCR positive findingses;Passage 1 and 2 is pSpCas9
(BB) -2A-Puro-sgRNA1 and pSpCas9 (BB) -2A-Puro-sgRNA5 combinations knock out PCR negative findingses, and passage 6 is right
According to 293T cell PCR results;Passage M is DNA molecular amount standard.
Fig. 3 is pSpCas9 (BB) -2A-Puro-sgRNA1 and pSpCas9 (BB) -2A-Puro- in the embodiment of the present invention 2
SgRNA3 pairing sgRNA combinations knock out checking sequencing result schematic diagram in 293T.
Fig. 4 is pSpCas9 (BB) -2A-Puro-sgRNA2 and pSpCas9 (BB) -2A-Puro- in the embodiment of the present invention 2
SgRNA5 pairing sgRNA combinations knock out result schematic diagram in 293T;Wherein, passage 1 is pSpCas9 (BB) -2A-Puro-
SgRNA2 and pSpCas9 (BB) -2A-Puro-sgRNA5 combinations knock out the positive findingses of PCR, and passage 2,3,4,5,6,7,8 is
PSpCas9 (BB) -2A-Puro-sgRNA2 and pSpCas9 (BB) -2A-Puro-sgRNA4 combinations knock out PCR negative findingses, lead to
Road 9 is control 293T cell PCR results;Passage M is DNA molecular amount standard.
Fig. 5 is pSpCas9 (BB) -2A-Puro-sgRNA2 and pSpCas9 (BB) -2A-Puro- in the embodiment of the present invention 2
SgRNA5 pairing sgRNA combinations knock out checking sequencing result schematic diagram in 293T.
Fig. 6 is that the monoclonal cell PCR checkings that 293T Jing medicine sieve separations are obtained after transfection in the embodiment of the present invention 2 knock out knot
Fruit schematic diagram;Wherein, passage 1 is the PCR positive findingses that 293T knocks out miR-126 monoclonal cells, and passage 2 is thin for control 293T
Born of the same parents PCR does not knock out result;Passage M is DNA molecular amount standard.
Fig. 7 is the monoclonal cell PCR of the knockout positive that 293T Jing medicine sieve separations are obtained after transfection in the embodiment of the present invention 2
Sequencing fragment result schematic diagram.
Fig. 8 is that miR-126 knocks out the stable strain fluorescent quantitation qPCR testing result schematic diagrams of 293T in the embodiment of the present invention 2;
Wherein, 293Tblank is the fluorescent quantitation qPCR results that 293T compared with control cells does not knock out miR-126, and 293T cloneD2 are
293T knocks out the fluorescent quantitation qPCR results of miR-126 positive colony D2 cells.
Fig. 9 is that the monoclonal cell PCR checkings that A549 Jing medicine sieve separations are obtained after transfection in the embodiment of the present invention 3 knock out knot
Fruit schematic diagram;Wherein, passage 1,2,3,4,5,6 are A549 knocks out PCR positive findingses after miR-126, and passage 7 is control A549
The PCR results that cell is knocked out without miR-126;Passage M is DNA molecular amount standard.
Figure 10 is the monoclonal cell of the knockout positive that A549 Jing medicine sieve separations are obtained after transfection in the embodiment of the present invention 3
PCR fragment sequencing result schematic diagram.
Figure 11 is that the monoclonal cell PCR checkings that HUVEC Jing medicine sieve separations are obtained after transfection in the embodiment of the present invention 4 are knocked out
Result schematic diagram;Wherein, passage 2 is the positive PCR results that HUVEC knocks out miR-126, and passage 1,3,4 is control HUVEC cells
The PCR results that miR-126 is not knocked out;Passage M is DNA molecular amount standard.
Figure 12 is the Dan Ke of the knockout miR-126 positives that HUVEC Jing medicine sieve separations are obtained after transfection in the embodiment of the present invention 4
Grand cell PCR fragment sequencing result schematic diagram.
Figure 13 is that T47D cell PCR checkings Jing after medicine sieve knock out result schematic diagram after transfection in the embodiment of the present invention 5;Its
In, passage 1,2 is the positive PCR results that T47D cell samples knock out miR-126, and passage 3,4 is control T47D cell miR-126
The PCR results not knocked out;Passage M is DNA molecular amount standard.
Figure 14 is that T47D miR-126 Jing after medicine sieve knock out positive cell PCR fragment survey after transfection in the embodiment of the present invention 5
Sequence result schematic diagram.
Figure 15 is that miR-126 gene orders completely knock out schematic diagram.
Specific embodiment
This invention is expanded on further with reference to specific embodiment.It should be understood that particular implementation described here
By way of example representing, limitation of the present invention is not intended as.Without departing from the scope of the invention, the present invention
Principal character can be used for various embodiments.
The vector construction of embodiment 1.
(1) miR-126 drone designs
For miR-126 genes (gene name miR-126, gene I/D number:406913, gene details are shown in http://
Www.ncbi.nlm.nih.gov/gene/406913), download from the website and obtain miR-126 genome sequences:
5’-CGCTGGCGACGGGACATTATTACTTTTGGTACGCGCTGTGACACTTCAAACTCGTACCGTGAGT
AATAATGCGCCGTCCACGGCA-3 ', as shown in SEQ ID NO.1.
Using online software Feng Zhang lab's Target Finder (http://crispr.mit.edu/) set
Meter sgRNA, is input into the sequence of miR-126 genome sequences and each 50bp of its upstream and downstream, arranges and retrieve some sgRNA sequences of acquisition
Row, by off-target (missing the target) information for analyzing positions and the sgRNA of the sgRNA in gene order, therefrom distinguish
The optimum target sequence of upstream 2, and 3, downstream target sequence are selected, it is specific as follows:
Upstream:
sgRNA-1:TAATGTCCCGTCGCCAGCGG, as shown in SEQ ID NO.2;
sgRNA-2:GCCACGCCTCCGCTGGCGAC, as shown in SEQ ID NO.3;
Downstream:
sgRNA-3:TCTCAGCGGCGTTTTCGATG, as shown in SEQ ID NO.4;
sgRNA-4:GAGTAATAATGCGCCGTCCA, as shown in SEQ ID NO.5;
sgRNA-5:TTTCGATGCGGTGCCGTGGA, as shown in SEQ ID NO.6;
(2) sgRNA fragments are synthesized
According to sgRNA intend cloning into carrier pSpCas9 (BB) -2A-Puro (purchased from Addgene) restriction enzyme site
The information of Bbs I, above-mentioned sgRNA sequences are obtained after complementary seriess, along with the corresponding viscosity end of Bbs I restricted enzyme
End.Obtain following sequence:
sgRNA-1F:CcacgTAATGTCCCGTCGCCAGCGG, as shown in SEQ ID NO.7;
sgRNA-1R:AaacCCGCTGGCGACGGGACATTAc, as shown in SEQ ID NO.8;
sgRNA-2F:CcacGCCACGCCTCCGCTGGCGAC, as shown in SEQ ID NO.9;
sgRNA-2R:Aaac GTCGCCAGCGGAGGCGTGGC, as shown in SEQ ID NO.10;
SgRNA-3F ccacgTCTCAGCGGCGTTTTCGATG, as shown in SEQ ID NO.11;
SgRNA-3R aaacCATCGAAAACGCCGCTGAGAC, as shown in SEQ ID NO.12;
SgRNA-4F ccacGAGTAATAATGCGCCGTCCA, as shown in SEQ ID NO.13;
SgRNA-4R aaacTGGACGGCGCATTATTACTC, as shown in SEQ ID NO.14;
SgRNA-5F ccacgTTTCGATGCGGTGCCGTGGA, as shown in SEQ ID NO.15;
SgRNA-5R aaacTCCACGGCACCGCATCGAAAc, as shown in SEQ ID NO.16.
By above-mentioned sequence, send Thermofisher companies synthesizing single-stranded nucleotide chain.
(3) sgRNA fragments connect with expression vector and convert
1 μ g pSpCas9 (BB) -2A-Puro are carried out into single endonuclease digestion with Bbs I (being purchased from NEB companies, article No. R0539S),
After 37 DEG C of water-baths 1 hour, linearisation is carried using PCR primer purification kit (being purchased from Tiagen companies, article No. is DP204)
Body carries out purification.
The dry powder of the F and R chains of every group of synthetic sgRNA is diluted to into 100 μM, 1 μ L solution is respectively taken and is mixed in PCR pipe
It is interior, gradually it is down to 22 DEG C from 95 DEG C with 1.5 DEG C per minute in PCR instrument.
Using T4DNA ligases (be purchased from Takara companies, article No. 6022Q) by linearizing pSpCas9 (the BB) -2A- of 1 μ L
Puro is connected with the sgRNA fragments after 0.5 μ L annealing, and linked system is shown in Table 1:
Table 1
sgRNA | 0.5μL |
Linearizing pSpCas9 (BB) -2A-Puro | 1μL |
DNAsolution I | 5μL |
ddH2O | up to 10μL |
After 16 DEG C connect 15 minutes, whole connection products are added to 100 μ L bacillus coli DH 5 alpha competent cell (pfu
≥108) in, after placing 30 minutes on ice, in 42 DEG C of water-bath heat shocks 90 seconds, then it is placed in 5 minutes on ice, add in super-clean bench
1mL LB fluid mediums (Luria-Bertani culture medium), 37 DEG C of shaken cultivation 1 hour, take 500 μ L and coat containing Amp
On the LB solid mediums of (Ampicillin, ampicillin), after liquid absorption is finished, 37 DEG C of overnight incubations are inverted in.
(4) identify after converting
The single bacterium colony that the flat board of DH5 α competent cells bacterium solution coating after conversion grows is reflected using bacterium colony PCR methods
It is fixed.Bacterium colony PCR identifications are as follows with primer:
Primer F:5'GACTATCATATGCTTACCG 3', as shown in SEQ ID NO.17;
Primer R:5'CCAAGTGGGCAGTTTACC 3', as shown in SEQ ID NO.18;
Bacterium solution PCR system is as shown in table 2:
Table 2
Composition | Volume |
10×buffer | 2.5μL |
primer F(10μM) | 0.2μL |
primer R(10μM) | 0.2μL |
dNTPs(2.5mM) | 2μL |
RTaq enzymes (50U/ μ L) | 0.5μL |
Bacterium colony | Pick a little |
ddH2O | up to 25μL |
PCR programs are 95 DEG C of 10min;95 DEG C of 20sec, 55 DEG C of 30sec, 72 DEG C of 30sec, totally 35 circulations;72℃
10min.The agarose gel electrophoresiies of PCR primer Jing 1% for obtaining are gone into detection, the single bacterium colony of 100bp or so amplified fragments occurs
It is the single bacterium colony containing positive colony (as shown in figure 1, PCR primer clip size is big with the 100bp fragments of DNA molecular amount standard
It is little close, and 1000bp fragments are the most paillette section of the molecular weight standard).By the inoculation 2mL LB liquid trainings of positive colony single bacterium colony
In foster base, 1mL bacterium solutions are taken after 37 DEG C of overnight shaking cultures for conservation, remaining 1mL bacterium solutions send sequencing company, and (Shanghai Mei Ji is biological
Pharmaceutical Technology Co., Ltd) carry out sequence verification.The sequencing result Jing Blast analysis shows for obtaining, sgRNA fragments are cloned
In entering pSpCas9 (BB) -2A-Puro plasmids, and sequence is consistent, can be used for subsequent experimental.Carrier with sgRNA is ordered respectively
Entitled pSpCas9 (BB) -2A-Puro-sgRNA1, pSpCas9 (BB) -2A-Puro-sgRNA2, pSpCas9 (BB) -2A-
Puro-sgRNA3, pSpCas9 (BB) -2A-Puro-sgRNA4 and pSpCas9 (BB) -2A-Puro-sgRNA5.
MiR-126 knocks out activity identification and 293T knockout miR-126 are thin in the plasmid transfection of embodiment 2. and 293T cells
The structure of born of the same parents' model
(1) plasmid extraction
By in embodiment 1 through sequence verification, respectively comprising sgRNA-1, sgRNA-2, sgRNA-3, sgRNA-4,
The bacillus coli DH 5 alpha of pSpCas9 (the BB) -2A-Puro plasmids of sgRNA-5 fragments is each inoculated in 5mL LB fluid mediums
In, 37 DEG C of overnight shaking cultures.Using endotoxin-free mini-scale plasmid extracts kit, (test kit is Omega companies product, article No.
For D6948-02) plasmid extraction is carried out to these bacterium solutions.Plasmid after extracting again in super-clean bench dehydrated alcohol precipitation after, with nothing
Bacterium water dissolution carries out the aseptic process to plasmid.
(2) a pair pSpCas9 (BB) -2A-Puro-sgRNA plasmids containing sgRNA of 293T cell transfectings
1) 293T cell culture
By 293T cells with 3 × 105The density of cells/well is laid in 24 orifice plates, it is ensured that each hole cell growth state is good,
Density is similar, treats cell for monolayer and in mid-log phase, and cell confluency degree is transfected up to 80% or so.
2) transfection composite is prepared:
According to the pairing of table 3, a pair pSpCas9 (BB) -2A-Puro-sgRNA plasmids containing sgRNA are passed through
The liposome reagents of Lipofectamine 2000 transfect 293T cells.
Upstream and downstream plasmid containing the sgRNA matching table of table 3
Sequence number | Upstream sgRNA plasmids | Downstream sgRNA plasmids |
1 | pSpCas9(BB)-2A-Puro-sgRNA1 | pSpCas9(BB)-2A-Puro-sgRNA3 |
2 | pSpCas9(BB)-2A-Puro-sgRNA1 | pSpCas9(BB)-2A-Puro-sgRNA5 |
3 | pSpCas9(BB)-2A-Puro-sgRNA2 | pSpCas9(BB)-2A-Puro-sgRNA4 |
4 | pSpCas9(BB)-2A-Puro-sgRNA2 | pSpCas9(BB)-2A-Puro-sgRNA5 |
2 aseptic EP pipes are taken, plasmid 0.8 is diluted in the Opti-MEM culture medium of the serum-free antibiotic-free of 50 μ L respectively
The Lipofectamine 2000 of μ g and 2 μ L, is stored at room temperature 5 minutes, and the plasmid of dilution and Lipofectamine 2000 are mixed
Close, the transfection composite of 100 μ L is obtained.After gently mixing, it is incubated at room temperature 20 minutes.
3) cell transfecting:
Above-mentioned transfection composite is added in corresponding 24 orifice plate, Tissue Culture Plate is softly rocked back and forth, cell is put
Return 37 DEG C of 5%CO2After incubator continues to cultivate 6 hours, culture medium is replaced by into complete medium, cell is placed in 37 DEG C by continuation
5%CO2Incubator culture.
4) medicine sieve
After transfection 24 hours, culture medium is replaced by into the complete medium containing 2 μ g/mL puromycin.Per 24 hours more
Change the complete medium of a drug containing, continuous three days.Green florescent signal is examined under a microscope daily, is recorded cellular
State.
(3) CRISPR/Cas9 knocks out efficiency checking
1) the knockout efficiency in PCR sequence measurements checking genomic level
293T cells and the 293T cells without transfection after medicine sieve are collected, is tried using submicrosample genotype identification
Agent box (Nanjing Yao Shunyu bio tech ltd, KC-101) carries out sample process, and is entered using PCR primer as shown in table 4
Performing PCR amplification identification.
Table 4
* primer sequence (5'--3') | * Primer |
GAGGGAGGATAGGTGGGTTC, as shown in SEQ ID NO.19 | mir126-test-Fw |
AGGCAGAGCCAGAAGACTCA, as shown in SEQ ID NO.20 | mir126-test-Rv |
GCACTGGAATCTGGGCGGAAGG, as shown in SEQ ID NO.21 | mir126-test-2-Fw |
AGAGCCAGGCGCTGGGTCAC, as shown in SEQ ID NO.22 | mir126-test-2-Rv |
PCR reaction systems are as shown in table 5:
Table 5
94℃5min;94 DEG C of 30sec, 62 DEG C of 30sec, 72 DEG C of 30sec, totally 35 circulations;72℃10min.PCR is expanded
10 times of product dilution, by template of dilution the second wheel PCR is carried out, and PCR system is as shown in table 6:
Table 6
94℃5min;94 DEG C of 30sec, 62 DEG C of 30sec, 72 DEG C of 2min, totally 35 circulations;72℃5min.PCR amplifications are produced
The agarose gel electrophoresiies of thing Jing 1% detect (result is shown in Fig. 2, shown in Fig. 4), choose with the 293T cell sample bands without transfection
Compare PCR primer substantially less than normal to send to sequencing (Shanghai Major Biological Medical Technology Co., Ltd.) (result is shown in Fig. 3, Fig. 5 institutes
Show).
Sequencing result is analyzed using Blast and is shown, by pSpCas9 (BB) -2A-Puro-sgRNA1 and pSpCas9
(BB) -2A-Puro-sgRNA3 and by pSpCas9 (BB) -2A-Puro-sgRNA2 and pSpCas9 (BB) -2A-Puro-
The sgRNA plasmid combinations of sgRNA5 compositions can completely knock out miR-126 genome sequences in 293T cells, and pSpCas9 (BB)-
2A-Puro-sgRNA1 and pSpCas9 (BB) -2A-Puro-sgRNA3 combinations are deleted and can obtain the more of positive findingses, because
This efficiency is more preferably.Other sgRNA combinations of pairs knock out the result for feminine gender, it is impossible to effectively knock out miR-126 in 293T cells
Genome sequence.
Thus, pSpCas9 (BB) -2A-Puro-sgRNA1 and pSpCas9 (BB) -2A-Puro-sgRNA3 are selected,
PSpCas9 (BB) -2A-Puro-sgRNA2 and pSpCas9 (BB) -2A-Puro-sgRNA5 are that miR-126 full-length genes knock out examination
The sgRNA combinations of agent box;It is preferred that pSpCas9 (BB) -2A-Puro-sgRNA1 and pSpCas9 (BB) -2A-Puro-sgRNA3 groups
Close.
(4) build miR-126 and knock out 293T cell models and qPCR test knockout efficiency
It is miR- by selected pSpCas9 (BB) -2A-Puro-sgRNA1 and pSpCas9 (BB) -2A-Puro-sgRNA3
126 full-length genes knock out the sgRNA combinations of test kit, according to (1) the step of embodiment 2 --- (3) obtain being knocked out containing miR-126
293T cell lines, will have verified that containing miR-126 knock out 293T cell countings after, be diluted to 2/hole quantity be inoculated with 24 holes
Plate, is placed in 37 DEG C, 5%CO2Incubator culture two weeks, period observes daily monoclonal growth conditions in orifice plate.After two weeks, such as
Monoclonal grows into cell mass in orifice plate, takes cell in cell mass and enters performing PCR checking sequencing, sees whether the cell mass is knockout
The 293T monoclonal cells group (the results detailed in shown in Fig. 6) of miR-126, PCR results show the band of 293T monoclonal cells group
The PCR bands of control 293T cells are significantly less than, (Shanghai Mei Ji is biological to send sequencing by the PCR primer that 293T monoclonal cells are rolled into a ball
Pharmaceutical Technology Co., Ltd, as a result as shown in Figure 7), sequencing result Jing Blast comparisons, miR-126 genomic coding sequences
It is knocked completely in 293T monoclonal cells group (monoclonal is named as D2), will verifies that correct monoclonal cell group D2 expands
Culture, the 293T cell models that so far miR-126 is knocked out are successfully constructed.
The 293T for successfully constructing is knocked out into miR-126 cytotostatics strain clone D2 amplification culture and QIAGEN is utilized
MiRNeasy Mini Kit (QIAGEN, article No. 217004) carry out RNA (comprising microRNA) extracting, and the RNA after extracting is utilized
MiScript II RT Kit (QIAGEN, article No. 218160) is inverted, system such as table 7:
Table 7
37℃60min;After the cDNA for having inverted is diluted 10 times by 95 DEG C of 5min, using primer as shown in table 8 qPCR is carried out.
Table 8
* primer sequence (5'--3') | * Primer |
TCGTACCGTGAGTAATAATGCG, as shown in SEQ ID NO.23 | mir126Fw |
GATTGAATCGAGCACCAGTTAC, as shown in SEQ ID NO.24 | common q |
TTCGTGAAGCGTTCCATATTTT, as shown in SEQ ID NO.25 | U6Fw |
PCR reaction systems such as table 9:
Table 9
95℃2min;94 DEG C of 15sec, 60 DEG C of 1min totally 40 circulations;Quantitative real time PCR Instrument SYBR passages during 60 DEG C of 1min
Collection signal.After experiment terminates, software analysis experimental result is carried using quantitative real time PCR Instrument, obtained 293T monoclonals D2 (
Checking knocks out the stable strain of successful 239T monoclonals) miR-126 relative to itself U6 expression, and blank sample
MiR-126 relative to itself U6 expression.MiR-126 relative expression quantities with blank sample are determined as standard
Justice is 100% for expression efficiency, so as to calculate 293T monoclonal D2 in the expression efficiency of miR-126 be that 5.37% (result is such as
Shown in Fig. 8), show using pSpCas9 (BB) -2A-Puro-sgRNA1 and pSpCas9 (BB) -2A-Puro-sgRNA3sgRNA
Combination can knock out miR-126 in 293T, and knock out efficiency up to 94.63%.
Embodiment 3 builds the lung carcinoma cell model that miR-126 is knocked out
1) lung cell A549 cell transfecting
PSpCas9 (BB) -2A-Puro-sgRNA1, pSpCas9 (BB) -2A-Puro-sgRNA3 are utilized
The cotransfection lung cell A549s of Lipofectamine 2000, after transfecting 24 hours, using complete containing 2 μ g/mL puromycin
Full culture medium carries out medicine sieve, after medicine is sieved three days, collects cell.
2) activity checking is knocked out
A549 cells and the A549 cells without transfection after medicine sieve are collected, is tried using submicrosample genotype identification
Agent box (Nanjing Yao Shunyu bio tech ltd, KC-101) carries out sample process, and is entered using PCR primer as shown in table 10
Performing PCR amplification identification.
Table 10
* primer sequence (5'--3') | * Primer |
GAGGGAGGATAGGTGGGTTC, as shown in SEQ ID NO.19 | mir126-test-Fw |
AGGCAGAGCCAGAAGACTCA, as shown in SEQ ID NO.20 | mir126-test-Rv |
GCACTGGAATCTGGGCGGAAGG, as shown in SEQ ID NO.21 | mir126-test-2-Fw |
AGAGCCAGGCGCTGGGTCAC, as shown in SEQ ID NO.22 | mir126-test-2-Rv |
PCR reaction systems such as table 11:
Table 11
94℃5min;94 DEG C of 30sec, 62 DEG C of 30sec, 72 DEG C of 30sec, totally 35 circulations;72℃10min.PCR is expanded
10 times of product dilution, by template of dilution the second wheel PCR, PCR system such as table 12 are carried out:
Table 12
94℃5min;94 DEG C of 30sec, 62 DEG C of 30sec, 72 DEG C of 2min, totally 35 circulations;72℃5min.PCR amplifications are produced
The agarose gel electrophoresiies of thing Jing 1% detect, choose PCR substantially less than normal compared with the A549 cell sample bands without transfection and produce
Thing sends to sequencing (Shanghai Major Biological Medical Technology Co., Ltd.).Sequencing result is analyzed using Blast and is shown, miR-
126 fragments are effectively knocked out in genome.
3) the lung cancer cell line A549 monoclonals that miR-126 is knocked out are separated
To have verified that the quantity for being diluted to 2/hole connects after the lung cancer cell line A549 cell countings containing miR-126 knockouts
24 orifice plates are planted, 37 DEG C is placed in, 5%CO2Incubator culture two weeks, period observes daily monoclonal growth conditions in orifice plate.Two
Monoclonal grows into cell mass in Zhou Hou, such as orifice plate, takes cell in cell mass and enters performing PCR checking sequencing, whether sees the cell mass
To knock out the A549 monoclonal cells group (the results detailed in shown in Fig. 9) of miR-126, PCR results show 6 monoclonal bars of A549
Band is significantly less than the PCR bands of control A549 cells, and the PCR primer of monoclonal A2 send sequencing in 6 monoclonals of random choose
(Shanghai Major Biological Medical Technology Co., Ltd., as a result as shown in Figure 10), sequencing result Jing Blast comparisons, miR-126
It is knocked completely in A549 monoclonal A2, correct monoclonal cell group culture amplification culture will be verified, so far miR-126 strikes
The A549 cell models for removing are successfully constructed.
Embodiment 4 builds the endothelial cell model that miR-126 is knocked out
1) Human umbilical vein endothelial cells HUVEC cell transfecting
PSpCas9 (BB) -2A-Puro-sgRNA1, pSpCas9 (BB) -2A-Puro-sgRNA3 are utilized
Cotransfection Human umbilical vein endothelial cells HUVEC of Lipofectamine 2000, after transfecting 24 hours, using containing 2 μ g/mL
The complete medium of puromycin carries out medicine sieve, after medicine is sieved three days, collects cell.
2) activity checking is knocked out
HUVEC cells and the HUVEC cells without transfection after medicine sieve are collected, using submicrosample genotype identification
Test kit (Nanjing Yao Shunyu bio tech ltd, KC-101) carries out sample process, and using PCR primer as shown in table 13
Enter performing PCR amplification identification.
Table 13
* primer sequence (5'--3') | * Primer |
GAGGGAGGATAGGTGGGTTC, as shown in SEQ ID NO.19 | mir126-test-Fw |
AGGCAGAGCCAGAAGACTCA, as shown in SEQ ID NO.20 | mir126-test-Rv |
GCACTGGAATCTGGGCGGAAGG, as shown in SEQ ID NO.21 | mir126-test-2-Fw |
AGAGCCAGGCGCTGGGTCAC, as shown in SEQ ID NO.22 | mir126-test-2-Rv |
PCR reaction systems such as table 14:
Table 14
94℃5min;94 DEG C of 30sec, 62 DEG C of 30sec, 72 DEG C of 30sec, totally 35 circulations;72℃10min.PCR is expanded
10 times of product dilution, by template of dilution the second wheel PCR, PCR system such as table 15 are carried out:
Table 15
94℃5min;94 DEG C of 30sec, 62 DEG C of 30sec, 72 DEG C of 2min, totally 35 circulations;72℃5min.PCR amplifications are produced
The detection of the agarose gel electrophoresiies of thing Jing 1%, chooses PCR substantially less than normal compared with the HUVEC cell sample bands without transfection
Product sends to sequencing (Shanghai Major Biological Medical Technology Co., Ltd.).Sequencing result is analyzed using Blast and is shown, miR-
126 fragments are effectively knocked out in genome.
3) the HUVEC monoclonals that miR-126 is knocked out are separated
To have verified that after the HUVEC cell countings containing miR-126 knockouts, the quantity for being diluted to 2/hole is inoculated with 24 orifice plates,
37 DEG C are placed in, 5%CO2Incubator culture two weeks, period observes daily monoclonal growth conditions in orifice plate.After two weeks, such as hole
Monoclonal grows into cell mass in plate, takes cell in cell mass and enters performing PCR checking sequencing, sees whether the cell mass is to knock out miR-
126 HUVEC monoclonal cells group (the results detailed in shown in Figure 11), PCR results show that the monoclonal cell group band of HUVEC is bright
The aobvious PCR bands less than control HUVEC cells, by the PCR primer of HUVEC monoclonal cells group (being named as monoclonal H1) survey is sent
Sequence (Shanghai Major Biological Medical Technology Co., Ltd., as a result as shown in figure 12), sequencing result Jing Blast comparisons, miR-
126 are knocked completely in HUVEC monoclonal cells group H1, will verify correct monoclonal cell group culture amplification culture, extremely
The HUVEC cell models that this miR-126 is knocked out are successfully constructed.
Breast cancer cell T47D cell lines miR-126 of embodiment 5 are knocked out
1) breast cancer cell T47D cell transfectings
PSpCas9 (BB) -2A-Puro-sgRNA1, pSpCas9 (BB) -2A-Puro-sgRNA3 are utilized
The cotransfection breast cancer cell T47D of Lipofectamine 2000, after transfecting 24 hours, utilize containing 2 μ g/mL puromycin
Complete medium carries out medicine sieve, after medicine is sieved three days, collects cell.
2) activity checking is knocked out
T47D cells and the T47D cells without transfection after medicine sieve are collected, is tried using submicrosample genotype identification
Agent box (Nanjing Yao Shunyu bio tech ltd, KC-101) carries out sample process, and using PCR primer as shown in table 16
Enter performing PCR amplification identification.
Table 16
* primer sequence (5'--3') | * Primer |
GAGGGAGGATAGGTGGGTTC, as shown in SEQ ID NO.19 | mir126-test-Fw |
AGGCAGAGCCAGAAGACTCA, as shown in SEQ ID NO.20 | mir126-test-Rv |
GCACTGGAATCTGGGCGGAAGG, as shown in SEQ ID NO.21 | mir126-test-2-Fw |
AGAGCCAGGCGCTGGGTCAC, as shown in SEQ ID NO.22 | mir126-test-2-Rv |
PCR reaction systems such as table 17:
Table 17
94℃5min;94 DEG C of 30sec, 62 DEG C of 30sec, 72 DEG C of 30sec, totally 35 circulations;72℃10min.PCR is expanded
10 times of product dilution, by template of dilution the second wheel PCR, PCR system such as table 18 are carried out:
Table 18
94℃5min;94 DEG C of 30sec, 62 DEG C of 30sec, 72 DEG C of 2min, totally 35 circulations;72℃5min.PCR amplifications are produced
The agarose gel electrophoresiies of thing Jing 1% detect, choose PCR substantially less than normal compared with the T47D cell sample bands without transfection and produce
Thing (as shown in figure 13) sends to sequencing (Shanghai Major Biological Medical Technology Co., Ltd.).Sequencing result is (as shown in figure 14) to be utilized
Blast is analyzed and shows, miR-126 fragments are effectively knocked out in genome.
According to above-mentioned experimental result, present invention determine that for the sgRNA-1 and sgRNA-3 of miR-126 gene design;
SgRNA-2 and sgRNA-5 is effective sgRNA combined sequence, wherein can be used as miR- comprising sgRNA-1, sgRNA3 plasmid combinations
The Cas9 plasmids of the test kit that 126 full-length genes are knocked out.It is demonstrated experimentally that the test kit can effectively realize the clpp gene of cellular level
Remove, and can be used for various kinds of cell system including vehicles cells system 293T, tumor cell line:Lung cancer cell line A549, breast cancer cell
It is the gene knockout of cell line miR-126 such as T47D and endotheliocyte HUVEC systems.The miR-126 gene knockouts it is various thin
Born of the same parents' model, can be used for vascular endothelial cell poorly differentiated, and Several Kinds of Malignancy is such as:The gene of the aspects such as breast carcinoma, pulmonary carcinoma
Functional study, is that follow-up animal modeling is laid a good foundation, and is the instrument that the applied researcies such as further drug development are provided convenience.
Sequence table
<110>Shanghai Biotechnology Corporation
<120>A kind of miR-126 full-length genes based on CRISPR-Cas9 technologies knock out test kit and its application
<130>HJ16-12192
<160> 25
<170> PatentIn version 3.5
<210> 1
<211> 85
<212> DNA
<213>Artificial sequence
<400> 1
cgctggcgac gggacattat tacttttggt acgcgctgtg acacttcaaa ctcgtaccgt 60
gagtaataat gcgccgtcca cggca 85
<210> 2
<211> 20
<212> RNA
<213>Artificial sequence
<220>
<221> misc_RNA
<222> (1)..(20)
<223> sgRNA
<400> 2
taatgtcccg tcgccagcgg 20
<210> 3
<211> 20
<212> RNA
<213>Artificial sequence
<220>
<221> misc_RNA
<222> (1)..(20)
<223> sgRNA
<400> 3
gccacgcctc cgctggcgac 20
<210> 4
<211> 20
<212> RNA
<213>Artificial sequence
<220>
<221> misc_RNA
<222> (1)..(20)
<223> sgRNA
<400> 4
tctcagcggc gttttcgatg 20
<210> 5
<211> 20
<212> sgRNA
<213>Artificial sequence
<220>
<221> misc_RNA
<222> (1)..(20)
<223> sgRNA
<400> 5
gagtaataat gcgccgtcca 20
<210> 6
<211> 20
<212> RNA
<213>Artificial sequence
<220>
<221> misc_RNA
<222> (1)..(20)
<223> sgRNA
<400> 6
tttcgatgcg gtgccgtgga 20
<210> 7
<211> 25
<212> RNA
<213>Artificial sequence
<220>
<221> misc_RNA
<222> (1)..(25)
<223> sgRNA
<400> 7
ccacgtaatg tcccgtcgcc agcgg 25
<210> 8
<211> 25
<212> RNA
<213>Artificial sequence
<220>
<221> misc_RNA
<222> (1)..(25)
<223> sgRNA
<400> 8
aaacccgctg gcgacgggac attac 25
<210> 9
<211> 24
<212> RNA
<213>Artificial sequence
<220>
<221> misc_RNA
<222> (1)..(24)
<223> sgRNA
<400> 9
ccacgccacg cctccgctgg cgac 24
<210> 10
<211> 24
<212> RNA
<213>Artificial sequence
<220>
<221> misc_RNA
<222> (1)..(24)
<223> sgRNA
<400> 10
aaacgtcgcc agcggaggcg tggc 24
<210> 11
<211> 25
<212> RNA
<213>Artificial sequence
<220>
<221> misc_RNA
<222> (1)..(25)
<223> sgRNA
<400> 11
ccacgtctca gcggcgtttt cgatg 25
<210> 12
<211> 25
<212> RNA
<213>Artificial sequence
<220>
<221> misc_RNA
<222> (1)..(25)
<223> sgRNA
<400> 12
aaaccatcga aaacgccgct gagac 25
<210> 13
<211> 24
<212> RNA
<213>Artificial sequence
<220>
<221> misc_RNA
<222> (1)..(24)
<223> sgRNA
<400> 13
ccacgagtaa taatgcgccg tcca 24
<210> 14
<211> 24
<212> RNA
<213>Artificial sequence
<220>
<221> misc_RNA
<222> (1)..(24)
<223> sgRNA
<400> 14
aaactggacg gcgcattatt actc 24
<210> 15
<211> 25
<212> RNA
<213>Artificial sequence
<220>
<221> misc_RNA
<222> (1)..(25)
<223> sgRNA
<400> 15
ccacgtttcg atgcggtgcc gtgga 25
<210> 16
<211> 25
<212> RNA
<213>Artificial sequence
<220>
<221> misc_RNA
<222> (1)..(25)
<223> sgRNA
<400> 16
aaactccacg gcaccgcatc gaaac 25
<210> 17
<211> 19
<212> DNA
<213>Artificial sequence
<220>
<221> misc_feature
<223>Primer
<400> 17
gactatcata tgcttaccg 19
<210> 18
<211> 18
<212> DNA
<213>Artificial sequence
<220>
<221> misc_feature
<223>Primer
<400> 18
ccaagtgggc agtttacc 18
<210> 19
<211> 20
<212> DNA
<213>Artificial sequence
<220>
<221> misc_feature
<223>Primer
<400> 19
gagggaggat aggtgggttc 20
<210> 20
<211> 20
<212> DNA
<213>Artificial sequence
<220>
<221> misc_feature
<223>Primer
<400> 20
aggcagagcc agaagactca 20
<210> 21
<211> 22
<212> DNA
<213>Artificial sequence
<220>
<221> misc_feature
<223>Primer
<400> 21
gcactggaat ctgggcggaa gg 22
<210> 22
<211> 20
<212> DNA
<213>Artificial sequence
<220>
<221> misc_feature
<223>Primer
<400> 22
agagccaggc gctgggtcac 20
<210> 23
<211> 22
<212> DNA
<213>Artificial sequence
<220>
<221> misc_feature
<223>Primer
<400> 23
tcgtaccgtg agtaataatg cg 22
<210> 24
<211> 22
<212> DNA
<213>Artificial sequence
<220>
<221> misc_feature
<223>Primer
<400> 24
gattgaatcg agcaccagtt ac 22
<210> 25
<211> 22
<212> DNA
<213>Artificial sequence
<220>
<221> misc_feature
<223>Primer
<400> 25
ttcgtgaagc gttccatatt tt 22
Claims (9)
1. a kind of miR-126 full-length genes based on CRISPR-Cas9 technologies knock out test kit, it is characterised in that
The test kit is included by plasmid pSpCas9 (BB) -2A-Puro-sgRNA1 and plasmid pSpCas9 (BB) -2A-Puro-
The sgRNA plasmid combinations of sgRNA3 compositions;Plasmid pSpCas9 (the BB) -2A-Puro-sgRNA1, containing one section of complementation
DNA sequence, the DNA sequence can be transcribed into the target of miR-126 full-length gene of the specific recognition sequence as shown in SEQ ID NO.2
The sgRNA of mark sequence, the sgRNA can constitute special identification structure with trRNA, so that guiding Cas9 enzymes specifically shear miR-
126 gene pairss answer sequence;Plasmid pSpCas9 (the BB) -2A-Puro-sgRNA3, the DNA sequence containing one section of complementation should
DNA sequence can be transcribed into the target sequence of miR-126 full-length gene of the specific recognition sequence as shown in SEQ ID NO.4
SgRNA, the sgRNA can constitute special identification structure with trRNA, so that guiding Cas9 enzymes specifically shear miR-126 genes
Correspondence sequence;
Or, the test kit is included by plasmid pSpCas9 (BB) -2A-Puro-sgRNA2 and plasmid pSpCas9 (BB) -2A-
The sgRNA plasmid combinations of Puro-sgRNA5 compositions;Plasmid pSpCas9 (the BB) -2A-Puro-sgRNA2, containing one section mutually
The DNA sequence of benefit, the DNA sequence can be transcribed into miR-126 full-length gene of the specific recognition sequence as shown in SEQ ID NO.3
Target sequence sgRNA, the sgRNA can constitute special identification structure with trRNA, so that guiding Cas9 enzymes are specifically sheared
MiR-126 gene pairss answer sequence;Plasmid pSpCas9 (the BB) -2A-Puro-sgRNA5, the DNA sequence containing one section of complementation,
The DNA sequence can be transcribed into the target sequence of miR-126 full-length gene of the specific recognition sequence as shown in SEQ ID NO.6
SgRNA, the sgRNA can constitute special identification structure with trRNA, so that guiding Cas9 enzymes specifically shear miR-126 genes
Correspondence sequence.
2. test kit as claimed in claim 1, it is characterised in that plasmid pSpCas9 (the BB) -2A-Puro-sgRNA1 contains
Some complementary dna sequences are SEQ ID NO.7 and SEQ ID NO.8.
3. test kit as claimed in claim 1, it is characterised in that plasmid pSpCas9 (the BB) -2A-Puro-sgRNA3 contains
Some complementary dna sequences are SEQ ID NO.11 and SEQ ID NO.12.
4. test kit as claimed in claim 1, it is characterised in that plasmid pSpCas9 (the BB) -2A-Puro-sgRNA2 contains
Some complementary dna sequences are SEQ ID NO.9 and SEQ ID NO.10.
5. test kit as claimed in claim 1, it is characterised in that plasmid pSpCas9 (the BB) -2A-Puro-sgRNA5 contains
Some complementary dna sequences are SEQ ID NO.15 and SEQ ID NO.16.
6. test kit as claimed in claim 1, it is characterised in that plasmid pSpCas9 (the BB) -2A-Puro-sgRNA1 and
The sgRNA plasmid combinations of plasmid pSpCas9 (BB) -2A-Puro-sgRNA3 compositions, plasmid pSpCas9 (the BB) -2A-
The sgRNA plasmid combinations of Puro-sgRNA2 and plasmid pSpCas9 (BB) -2A-Puro-sgRNA5 compositions are with including following step
What rapid method built:
Step one, by target software design preferably a number of miR-126 upstream region of gene and downstream CRISPR-Cas9 targets
Mark sequence, it is specific as follows:
Upstream:
sgRNA-1:TAATGTCCCGTCGCCAGCGG, as shown in SEQ ID NO.2;
sgRNA-2:GCCACGCCTCCGCTGGCGAC, as shown in SEQ ID NO.3;
Downstream:
sgRNA-3:TCTCAGCGGCGTTTTCGATG, as shown in SEQ ID NO.4;
sgRNA-4:GAGTAATAATGCGCCGTCCA, as shown in SEQ ID NO.5;
sgRNA-5:TTTCGATGCGGTGCCGTGGA, as shown in SEQ ID NO.6;
Step 2, separately designs sgRNA fragment of the synthesis for upstream and downstream target sequence, and is building up in plasmid vector;
The sgRNA fragment sequences are as follows:
sgRNA-1F:CcacgTAATGTCCCGTCGCCAGCGG, as shown in SEQ ID NO.7;
sgRNA-1R:AaacCCGCTGGCGACGGGACATTAc, as shown in SEQ ID NO.8;
sgRNA-2F:CcacGCCACGCCTCCGCTGGCGAC, as shown in SEQ ID NO.9;
sgRNA-2R:Aaac GTCGCCAGCGGAGGCGTGGC, as shown in SEQ ID NO.10;
SgRNA-3F ccacgTCTCAGCGGCGTTTTCGATG, as shown in SEQ ID NO.11;
SgRNA-3R aaacCATCGAAAACGCCGCTGAGAC, as shown in SEQ ID NO.12;
SgRNA-4F ccacGAGTAATAATGCGCCGTCCA, as shown in SEQ ID NO.13;
SgRNA-4R aaacTGGACGGCGCATTATTACTC, as shown in SEQ ID NO.14;
SgRNA-5F ccacgTTTCGATGCGGTGCCGTGGA, as shown in SEQ ID NO.15;
SgRNA-5R aaacTCCACGGCACCGCATCGAAAc, as shown in SEQ ID NO.16;
Step 3, by transfecting 293T cell strains, sgRNA and trRNA constitutes special identification structure, so as to guide Cas9 enzymes special
The corresponding sequence at strange land shearing miR-126 genes two ends, continues medicine sieve, obtains the cell strain of miR-126 full-length genes knockout;
Step 4, by extracting cell DNA, PCR amplifications, sequencing is determined and verifies, obtains the two groups of miR-126 bases for optimizing
SgRNA plasmid combinations because knocking out CRISPR-Cas9, i.e., described plasmid pSpCas9 (BB) -2A-Puro-sgRNA1 and plasmid
The sgRNA plasmid combinations of pSpCas9 (BB) -2A-Puro-sgRNA3 compositions, and the plasmid pSpCas9 (BB) -2A-
The sgRNA plasmid combinations of Puro-sgRNA2 and plasmid pSpCas9 (BB) -2A-Puro-sgRNA5 compositions.
7. test kit as claimed in claim 6, it is characterised in that described to be building up in plasmid vector in step 2, concrete bag
Include following steps:
(1) with pSpCas9 (BB) -2A-Puro plasmids as initial vector, single endonuclease digestion is carried out with Bbs I, linearized vector is carried out
Purification;
(2) synthetic sgRNA fragments are diluted and is annealed;
(3) linearizing pSpCas9 (BB) -2A-Puro is connected with the sgRNA fragments after annealing using T4DNA ligases, will
Whole connection products add the conversion of bacillus coli DH 5 alpha competent cell;
(4) single bacterium colony that the flat board of DH5 α competent cells bacterium solution coating after conversion grows is identified using bacterium colony PCR methods,
Obtain expression plasmid.
8. application of the test kit as described in any one of claim 1-7 in cell line miR-126 gene knockout product is prepared.
9. application as claimed in claim 8, it is characterised in that the cell line includes vehicles cells system 293T, tumor cell
System and endotheliocyte HUVEC systems.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611002317.4A CN106566838B (en) | 2016-11-14 | 2016-11-14 | A kind of miR-126 full-length gene knockout kit and its application based on CRISPR-Cas9 technology |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611002317.4A CN106566838B (en) | 2016-11-14 | 2016-11-14 | A kind of miR-126 full-length gene knockout kit and its application based on CRISPR-Cas9 technology |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106566838A true CN106566838A (en) | 2017-04-19 |
CN106566838B CN106566838B (en) | 2019-11-01 |
Family
ID=58542856
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611002317.4A Active CN106566838B (en) | 2016-11-14 | 2016-11-14 | A kind of miR-126 full-length gene knockout kit and its application based on CRISPR-Cas9 technology |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106566838B (en) |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9999671B2 (en) | 2013-09-06 | 2018-06-19 | President And Fellows Of Harvard College | Delivery of negatively charged proteins using cationic lipids |
CN108410907A (en) * | 2018-03-08 | 2018-08-17 | 湖南农业大学 | A method of HMGCR gene knockouts are realized based on CRISPR/Cas9 technologies |
US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
US10113163B2 (en) | 2016-08-03 | 2018-10-30 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US10167457B2 (en) | 2015-10-23 | 2019-01-01 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
CN110272921A (en) * | 2019-06-20 | 2019-09-24 | 武汉百翼生物科技有限公司 | A kind of safe and efficient CRISPR/Cas9 gene editing method |
US10465176B2 (en) | 2013-12-12 | 2019-11-05 | President And Fellows Of Harvard College | Cas variants for gene editing |
US10508298B2 (en) | 2013-08-09 | 2019-12-17 | President And Fellows Of Harvard College | Methods for identifying a target site of a CAS9 nuclease |
US10597679B2 (en) | 2013-09-06 | 2020-03-24 | President And Fellows Of Harvard College | Switchable Cas9 nucleases and uses thereof |
CN111257297A (en) * | 2020-03-31 | 2020-06-09 | 海南大学 | RNA detection method based on Cas14a enzyme |
US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
US10858639B2 (en) | 2013-09-06 | 2020-12-08 | President And Fellows Of Harvard College | CAS9 variants and uses thereof |
US11046948B2 (en) | 2013-08-22 | 2021-06-29 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US11268082B2 (en) | 2017-03-23 | 2022-03-08 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
US11306324B2 (en) | 2016-10-14 | 2022-04-19 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
CN114958850A (en) * | 2021-06-04 | 2022-08-30 | 南京大学 | Gene assembly, delivery system containing same and application thereof |
US11447770B1 (en) | 2019-03-19 | 2022-09-20 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
US11912985B2 (en) | 2020-05-08 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
US12281338B2 (en) | 2018-10-29 | 2025-04-22 | The Broad Institute, Inc. | Nucleobase editors comprising GeoCas9 and uses thereof |
US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
US12359218B2 (en) | 2023-03-03 | 2025-07-15 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1768139A (en) * | 2003-02-10 | 2006-05-03 | 独立行政法人产业技术总合研究所 | Regulation of gene expression by DNA interference |
WO2009082744A2 (en) * | 2007-12-22 | 2009-07-02 | Sloan-Kettering Institute For Cancer Research | Prognosis and interference-mediated treatment of breast cancer |
WO2011011061A2 (en) * | 2009-07-21 | 2011-01-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method of regulating angiogenesis and lymphangiogenesis, and a pharmaceutical composition for effecting anti-angiogenic and anti-lymphangiogenic cancer therapy |
CN102596255A (en) * | 2009-04-30 | 2012-07-18 | 圣拉斐尔德尔蒙特塔博基金中心 | Gene vector |
CN103820441A (en) * | 2014-03-04 | 2014-05-28 | 黄行许 | Method for human CTLA4 gene specific knockout through CRISPR-Cas9 (clustered regularly interspaced short palindromic repeat) and sgRNA(single guide RNA)for specially targeting CTLA4 gene |
CN105112445A (en) * | 2015-06-02 | 2015-12-02 | 广州辉园苑医药科技有限公司 | MiR-205 gene knockout kit based on CRISPR-Cas9 gene knockout technology |
-
2016
- 2016-11-14 CN CN201611002317.4A patent/CN106566838B/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1768139A (en) * | 2003-02-10 | 2006-05-03 | 独立行政法人产业技术总合研究所 | Regulation of gene expression by DNA interference |
WO2009082744A2 (en) * | 2007-12-22 | 2009-07-02 | Sloan-Kettering Institute For Cancer Research | Prognosis and interference-mediated treatment of breast cancer |
CN102596255A (en) * | 2009-04-30 | 2012-07-18 | 圣拉斐尔德尔蒙特塔博基金中心 | Gene vector |
WO2011011061A2 (en) * | 2009-07-21 | 2011-01-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method of regulating angiogenesis and lymphangiogenesis, and a pharmaceutical composition for effecting anti-angiogenic and anti-lymphangiogenic cancer therapy |
CN103820441A (en) * | 2014-03-04 | 2014-05-28 | 黄行许 | Method for human CTLA4 gene specific knockout through CRISPR-Cas9 (clustered regularly interspaced short palindromic repeat) and sgRNA(single guide RNA)for specially targeting CTLA4 gene |
CN105112445A (en) * | 2015-06-02 | 2015-12-02 | 广州辉园苑医药科技有限公司 | MiR-205 gene knockout kit based on CRISPR-Cas9 gene knockout technology |
Non-Patent Citations (3)
Title |
---|
ZEJUAN LI等: "Overexpression and knockout of miR-126 both promote leukemogenesis", 《BLOOD》 * |
单冬凯: "运用条件性敲除技术研究miR-126对动脉粥样硬化的抑制作用", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》 * |
崔永春等: "应用CRISPR-CAS9 技术制备miR-155 基因敲除小鼠", 《中国循环杂志》 * |
Cited By (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12006520B2 (en) | 2011-07-22 | 2024-06-11 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US11920181B2 (en) | 2013-08-09 | 2024-03-05 | President And Fellows Of Harvard College | Nuclease profiling system |
US10954548B2 (en) | 2013-08-09 | 2021-03-23 | President And Fellows Of Harvard College | Nuclease profiling system |
US10508298B2 (en) | 2013-08-09 | 2019-12-17 | President And Fellows Of Harvard College | Methods for identifying a target site of a CAS9 nuclease |
US11046948B2 (en) | 2013-08-22 | 2021-06-29 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US10858639B2 (en) | 2013-09-06 | 2020-12-08 | President And Fellows Of Harvard College | CAS9 variants and uses thereof |
US9999671B2 (en) | 2013-09-06 | 2018-06-19 | President And Fellows Of Harvard College | Delivery of negatively charged proteins using cationic lipids |
US11299755B2 (en) | 2013-09-06 | 2022-04-12 | President And Fellows Of Harvard College | Switchable CAS9 nucleases and uses thereof |
US10597679B2 (en) | 2013-09-06 | 2020-03-24 | President And Fellows Of Harvard College | Switchable Cas9 nucleases and uses thereof |
US10912833B2 (en) | 2013-09-06 | 2021-02-09 | President And Fellows Of Harvard College | Delivery of negatively charged proteins using cationic lipids |
US10682410B2 (en) | 2013-09-06 | 2020-06-16 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
US12215365B2 (en) | 2013-12-12 | 2025-02-04 | President And Fellows Of Harvard College | Cas variants for gene editing |
US11053481B2 (en) | 2013-12-12 | 2021-07-06 | President And Fellows Of Harvard College | Fusions of Cas9 domains and nucleic acid-editing domains |
US11124782B2 (en) | 2013-12-12 | 2021-09-21 | President And Fellows Of Harvard College | Cas variants for gene editing |
US10465176B2 (en) | 2013-12-12 | 2019-11-05 | President And Fellows Of Harvard College | Cas variants for gene editing |
US10704062B2 (en) | 2014-07-30 | 2020-07-07 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
US11578343B2 (en) | 2014-07-30 | 2023-02-14 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
US12043852B2 (en) | 2015-10-23 | 2024-07-23 | President And Fellows Of Harvard College | Evolved Cas9 proteins for gene editing |
US11214780B2 (en) | 2015-10-23 | 2022-01-04 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
US10167457B2 (en) | 2015-10-23 | 2019-01-01 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
US12344869B2 (en) | 2015-10-23 | 2025-07-01 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
US11702651B2 (en) | 2016-08-03 | 2023-07-18 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US10947530B2 (en) | 2016-08-03 | 2021-03-16 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US11999947B2 (en) | 2016-08-03 | 2024-06-04 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US10113163B2 (en) | 2016-08-03 | 2018-10-30 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
US12084663B2 (en) | 2016-08-24 | 2024-09-10 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
US11306324B2 (en) | 2016-10-14 | 2022-04-19 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
US11820969B2 (en) | 2016-12-23 | 2023-11-21 | President And Fellows Of Harvard College | Editing of CCR2 receptor gene to protect against HIV infection |
US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
US11268082B2 (en) | 2017-03-23 | 2022-03-08 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
US11932884B2 (en) | 2017-08-30 | 2024-03-19 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
CN108410907B (en) * | 2018-03-08 | 2021-08-27 | 湖南农业大学 | Method for realizing HMGCR gene knockout based on CRISPR/Cas9 technology |
CN108410907A (en) * | 2018-03-08 | 2018-08-17 | 湖南农业大学 | A method of HMGCR gene knockouts are realized based on CRISPR/Cas9 technologies |
US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
US12281338B2 (en) | 2018-10-29 | 2025-04-22 | The Broad Institute, Inc. | Nucleobase editors comprising GeoCas9 and uses thereof |
US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
US11447770B1 (en) | 2019-03-19 | 2022-09-20 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
US11795452B2 (en) | 2019-03-19 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
US11643652B2 (en) | 2019-03-19 | 2023-05-09 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
US12281303B2 (en) | 2019-03-19 | 2025-04-22 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
CN110272921A (en) * | 2019-06-20 | 2019-09-24 | 武汉百翼生物科技有限公司 | A kind of safe and efficient CRISPR/Cas9 gene editing method |
CN111257297B (en) * | 2020-03-31 | 2023-06-16 | 海南大学 | RNA detection method based on Cas14a enzyme |
CN111257297A (en) * | 2020-03-31 | 2020-06-09 | 海南大学 | RNA detection method based on Cas14a enzyme |
US11912985B2 (en) | 2020-05-08 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
US12031126B2 (en) | 2020-05-08 | 2024-07-09 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
CN114958850B (en) * | 2021-06-04 | 2023-12-15 | 南京大学 | A genetic component, a delivery system containing the genetic component and its application |
CN114958850A (en) * | 2021-06-04 | 2022-08-30 | 南京大学 | Gene assembly, delivery system containing same and application thereof |
US12359218B2 (en) | 2023-03-03 | 2025-07-15 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
Also Published As
Publication number | Publication date |
---|---|
CN106566838B (en) | 2019-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106566838B (en) | A kind of miR-126 full-length gene knockout kit and its application based on CRISPR-Cas9 technology | |
CN106047877B (en) | sgRNA and CRISPR/Cas9 lentivirus system for targeted knockout of FTO gene and application | |
CN105112445B (en) | A kind of miR-205 gene knockout kits based on CRISPR-Cas9 gene Knockouts | |
CN104178461B (en) | CAS9-carrying recombinant adenovirus and application thereof | |
CA3193961A1 (en) | Reprogrammable iscb nucleases and uses thereof | |
CN108690844A (en) | CRISPR/Cas9-gRNA target practices sequence pair, plasmid and the HD cell models of HTT | |
CN105821116A (en) | A detection method for directional knockout of sheep MSTN gene and its effect on myogenic differentiation | |
CN107794272A (en) | A kind of CRISPR genome editor's systems of high specific | |
CN107365793A (en) | A kind of method of extensive genome editor suitable for plant | |
WO2019086007A1 (en) | Sgrna for targeting and guiding cas9 protein to efficiently cleave tcr and b2m gene loci | |
CN111849979B (en) | sgRNA for targeted knockout of RPSA gene and construction method of RPSA gene knockout cell line | |
CN108949832A (en) | A kind of targeting vector and its application for knock-out pig GHR gene | |
CN109563510A (en) | MIR-302 presoma is used to be used to treat the composition and method of Human Lung Cancer as anticancer drug | |
CN106957857A (en) | A kind of method that utilization CRISPR/Cas9 systems knock out goat MSTN and FGF5 gene jointly | |
CN110438128B (en) | Method for knocking out pig CCAR1 gene by using CRISPR/Cas9 system | |
CN113416768B (en) | Application of PRKRA gene as target in inhibiting replication of peste des petits ruminants virus | |
CN117363653A (en) | Construction method and related application of DDR1 humanized animal model | |
CN104673797B (en) | Participate in long-chain non-coding RNA and its application of human body cell ionising radiation stress reaction | |
CN114107299B (en) | An sgRNA for targeted knockout of duck cGAS gene and its application | |
KR102648886B1 (en) | Method for modifying a target nucleic acid in the genome of a cell | |
CN108467855B (en) | Novel lung-specific metastatic liver cancer cells and their preparation | |
CN109706122A (en) | Method for constructing FSCN1 gene stable knockout cell line and plasmid or plasmid combination and application | |
CN114563330A (en) | A method for evaluating the correlation between self-protein and mesenchymal stem cell Th1 immune regulation | |
Chang et al. | Reporter gene knock-in into Marc-145 cells using CRISPR/Cas9-mediated homologous recombination | |
CN115786355B (en) | Application of Tango6 gene in promoting cell proliferation and method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |